Speaker: Lindsey A. George, MD
Are you or a loved one affected by hemophilia A? Curious about cutting-edge treatments that could change lives?
Join us for an exciting webinar where Dr. Lindsey A. George will shed light on recent advancements in gene therapy for hemophilia A. You'll learn about the potential of gene therapy to reduce bleeding episodes and improve the quality of life for those with hemophilia A. Dr. George will share the latest findings on how long the therapy's effects last and what this means for patients. Whether you're a patient, caregiver, healthcare professional, or just interested in medical breakthroughs, this webinar offers an accessible look into a promising future for hemophilia A treatment. Don't miss this opportunity to hear directly from a leading expert in the field. Join us to understand how science is working to transform the lives of those affected by hemophilia A.
NBDF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn about the latest in research, breakthrough developments, and more.
Register for Wednesday Webinar Series
Dr. George is an Assistant Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania and Director of Clinical In Vivo Gene Therapy at the Children’s Hospital of Philadelphia. Her laboratory studies the molecular basis of coagulation with a focus on mechanisms that regulate factor VIII/VIIIa cofactor function to improve understanding of associated disease states of deficiency, hemophilia A, or excess function with associated thrombosis. Ongoing studies in her group aim to exploit their biochemical insights of FVIII function to develop novel gene-based therapies for hemophilia A. Dr. George previously led early-phase, adeno-associated virus (AAV) mediated gene transfer trials for hemophilia A and B. Dr. George is a member of the Board of Directors of the American Society of Gene and Cell Therapy and participates in multiple national and international professional societies for hemostasis and gene therapy research.